Invention Grant
- Patent Title: Dosage regimes for the administration of an anti-CD19 ADC
-
Application No.: US17699065Application Date: 2022-03-18
-
Publication No.: US11938192B2Publication Date: 2024-03-26
- Inventor: Jay Marshall Feingold , David Rodney Ungar
- Applicant: ADC THERAPEUTICS SA , MEDIMMUNE LIMITED
- Applicant Address: CH Epalinges
- Assignee: MEDIMMUNE LIMITED,ADC THERAPEUTICS SA
- Current Assignee: MEDIMMUNE LIMITED,ADC THERAPEUTICS SA
- Current Assignee Address: GB Cambridge; CH Epalinges
- Agency: Casimir Jones SC
- Agent Lisa Mueller
- Priority: GB 09440 2017.06.14 GB 09444 2017.06.14 GB 10494 2017.06.30 GB 10495 2017.06.30 GB 20542 2017.12.08 GB 20543 2017.12.08 GB 02679 2018.02.20 GB 08473 2018.05.23
- Main IPC: A61K47/68
- IPC: A61K47/68 ; A61K31/5517 ; A61P35/02 ; C07K16/28 ; A61K9/00 ; A61K31/519 ; A61K31/573 ; A61K31/7068 ; A61K39/00
Abstract:
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
Public/Granted literature
- US20220280651A1 DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC Public/Granted day:2022-09-08
Information query
IPC分类:
